Intracoronary Administration of Levosimendan in Cardiac Surgery Patients

Status Terminated

Clinical Trial Summary

Incomplete recovery from ischemia causes stunned myocardium. Ischemia may be due to coronary artery disease or aortic cross-clamping during surgery. Stunning leads to myocardial dysfunction. It has been suggested that the mechanism responsible for the contractile depression in stunned myocardium is a decreased sensitivity of the myofibrils to calcium. Levosimendan is a calcium sensitizer, which has been shown to improve the function of stunned myocardium without obvious impairment of diastolic function. Systemic vasodilation and need of vasoconstrictive medication is usually apparent after administration of levosimendan. Colucci et al have demonstrated that with intracoronary administration of milrinone, another inodilator, systemic vasodilation could be excluded. If this is true with levosimendan, it may be possible to improve left ventricular hypo/dyskinesia without afterload reduction by adding levosimendan into cardioplegia solution.

The investigators hypotize that levosimendan, delivered together with cardioplegia, can improve LV dysfunction after opening of aortic cross-clamp in patients undergoing aortic valve and coronary artery bypass operation. Our primary endpoint is a change in cardiac output 15 min after separation from cardiopulmonary bypass compared to the baseline. Secondary endpoints are a change in LV ejection fraction from baseline to 5 min after sternal closure and cTnT/CK-MB on the first postoperative morning.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Myocardial Stunning

Clinical Trial Details

NCT number	NCT01500785
Study type	Interventional
Source	Tampere University Hospital
Contact
Status	Terminated
Phase	Phase 4
Start date	June 15, 2018
Completion date	September 11, 2019

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04830982` - Safety and Efficacy of IV Diazoxide as an Additive to Hyperkalemic Cardioplegia in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass	Phase 1
Completed	`NCT00213746` - Evaluation of Myocardial Viability by Means of Low-dose Dobutamine Gated SPECT (the DOGS Study)	N/A
Active, not recruiting	`NCT00123695` - Serial Echocardiography After Subarachnoid Hemorrhage	N/A
Completed	`NCT06450912` - Wall Strain Index Ratio as a Biomarker for Mechanical Complication of Hemorrhagic Myocardial Infarction
Completed	`NCT02545426` - Myocardial Stunning During Hemodialysis: Role of Dialyste Calcium Concentration	N/A
Completed	`NCT01179802` - Exercise-induced Changes in Cardiac Function & Morphology	N/A
Not yet recruiting	`NCT06308107` - Safety and Feasibility of Hyperkalemic Cardioplegia With Diazoxide in Cardiac Surgery (CPG-DZX) Trial	Phase 1
Recruiting	`NCT04448639` - Stunning in Takotsubo Versus Acute Myocardial Infarction
Withdrawn	`NCT02770183` - Rate of Left Ventricular Systolic Function's Recuperation After Cardiac Surgery With Extracorporeal Circulation.
Recruiting	`NCT05669144` - Co-transplantation of Mesenchymal Stem Cell Derived Exosomes and Autologous Mitochondria for Patients Candidate for CABG Surgery	Phase 1/Phase 2
Recruiting	`NCT05209230` - Is Myocardial Stunning Induced by Continuous Renal Replacement Therapy a Reality in Critically Ill Patients?	N/A
Withdrawn	`NCT02687269` - Ranolazine a Potential New Therapeutic Application	Phase 4